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The utility of using an enduranre test as welt :w a maximal 
axe&x test to assess the eff& of amlodiyii~~, a dibydrq- 
pyridine cplriuxn antagonist. was evaiuated in 16 PgtienP 
with angina Waris. Amlodipine, 10 mgiday, wm corn- 
prod with placebo in a double blind crowww study. A&r 
a ? week single blind placebo period, patients entered a 
double Mind crossowr phw alternating baveen 4 weeks 
of @acebo and 4 weeks of andodipine. Tb? two 4 week 
periods were wparatti by a I week sin& blind placebo 
washout period. The &cay of drug therapy was awEsed 
by frequency of angina, nitraglywin mnsumptiun. peak 
oxygen wmumption during a maximal treadmill oxercisa 
test and mdwance time during a separate xercise terl 
prrlmmed 8, 70% of ,be peak work capacity d.,arndnrd 
before randamiEa,,cn. 
Tkere was II rtductioo in angina frequency duricg the 
dwble Mind placebo and smladipine studies (sin+ blind 
plscebo I4 f 2 cpi%d~Yt rrrls, doubk btbad placebo 7 + 
2 spi.wdWi w&s [p i. O.w151. Pmlodipine 6 t 3 rpis&ri 
2 waak,. [Q < “.rnE,,, sbereas nitroglycerin Nns”mQli”n 
was reduced wi,h amlalipiac (single blind placebo 12 + S 
blind Qh%0 15.2 i 1.5 min, double Mind placebo lS.t?t 
2.1 min. amlodipinc 20.2 t 2.5 min III < O.uO51). The 
marLnat sxerck test are complementary in evaluating the 
efficacy of antiangiml therapy, but the endurance test may 
In this study the elF.cacy of amlodipine for treating patients 
with exertior.dl angina was assessed. Amlaiipine is a a!- 
cium antagonist of the dlhydropyridine class. Once a day 
administration provides sustained drug levels because the 
drug has a 20 to 40 h half-life I!). Previous studies (2.31 
suggested that doses of2.S to IO &day an effective therapy 
for hypertension and angina. 
Traditionally. the efficacy of antianginal therapy is cval- 
uated by changes in angina frequency and nitroglycerin 
consumption. Historical data often show ccnsiderable vari- 
alion and are subject to patient bias. Although maximal 
exercise testing provides objecrive meawrcmems. the rc- 
colts of tcslmg may not indicate the impact of therapy on 
dally activities lbat arc for the most part performed 81 ICYCI~ 
well below maximal capacity. Thercfare. we measured en- 
durance capacity at a fixed submaximal work load as another 
means of evaluating the efficacy of this antianginal agent. 
In normal subjects, the level of oxygen consumption or 
work load at which blood lactate accumulates during a 
maximal exercise test predicts endurance capacity W-8). 
Therefore. a further objective of this study was to evaluate 
the relation between the onset of lactalc accumuiation mea- 
sured dunnp a maximal exercise test and endurance capacity 
measured at a fixed submaximal work load m patwtr with 
coronary artery disease. We hypothesized that if this agent. 
by mechamsms uch as reduced myocardml oxygen demand 
or impruved oxygen deliver/ to Ihe myocardium. provided 
effective antianginal therapy. then the work load at which 
blood lactate accumulated would be higher on maximal 
exercise resting and endurance capacity on submaximal 
cxcrcisc lcsting would be prolonged. 
Methods 
Stug patienrs. Sixteen patients (1 I men. 5 women) with 
chronic stable angina pectoris were enrolled. To qualify for 
the study. each patient was required to experience angina 23 
times/week during a 2 week single blind placebo period and, 
in addition. demonstrate reproducible angina and ~1 mm 
horizontal or downsloping ST depression during maximal 
exercise testing at the end of weeks I and 2 of the single blind 
placebo period. None of the patients were participants i  an 
exercise rehabilitation program. None had sustained an 
acute myocardial infarction or had undergone coronary 
angioplasty or bypass grafting in the preceding 3 months. 
Subjects participated after giving informed cons&. 
Studv protocol. An inilial screening maximal exercise test 
was doi; afler treatment with all cardioactive drugs bad 
been discontinued for al week. Patients then received 
placebo in a single blind fashion-known lo the investigator 
but not to the patient-for 2 weeks. Patients were then 
randomized to receive either amlodipine (5 mglday for 2 
weeks followed by 10 mgiday for the next 2 weeks) or 
placebo with an identical appearance in a double blind 
fashion. This was followed by a I week single blind placebo 
washout period before treatments were crossed over in a 
double blind fashion for another 4 weeks. 
The eficocy of rhe drug ws evslusfed by diary records of 
frequency of angina and nitroglycerin consumption. maximal 
exercise testing with measurernerd of peak oxygen consump 
lion. time to the onset of angina and time to the onset of I 
mm of ST depression and by walking time during an endur- 
ance test performed at a fixed work load. 
The enduram exercise rest was performed on the day 
before the maximal exercise test at the end ofthe single blind 
placebo period (week 21 and at the end of each double blind 
placebo period (weeks 6 and II). 
Maximal exercise testing (inwemmtat work toad). Pa- 
tients were exercised on a treadmill until limited by symp- 
toms of angina, fatigue or dyspnea of a severe degree. The 
initial stage (1.7 mph and 096 grade for 3 mitt) was the:: 
followed by the regular stages of the Bruce protocol (9). 
During exercise testing a 12 lead clectrocardtogram (KG) 
was monitored at each stage and the lead that showed 
maximal ST depression at the initial screening treadmill test 
was monitored continuously. Computer-averaged beats 
were used to measure the ma&ude of ST depression M) ms 
past the .I point. Heart rate and blood pressure were re- 
coided at rest and during the last minute of evev stage of 
exercise. Blood pressure was measured with a cuff and 
stethoscope and loss of fifth phase Karatokoff sounds was 
used to detect diastolic pressure. The total duration of 
exercise. the time to I mm of ST depression and the time to 
onset of angina were noted. Ii patients did not experience 
angina or develop I mm of ST depression during the double 
blind test, then total exercise time to exhaustion was used 
for these variables. To evaluate the cKcct of amlodipine on 
submaximal variables, the highest common stage for each 
test that wan completed before the end of exercise was noted 
for each patient. At rest and during exercise, expired gas was 
colfected by way of a Hans Rudolph nonrebrealhing valve 
for measurement of oxygen consumption with the use of a 
Beckman metabolic cart. 
Estimation of oxygen consumption st the owt of blood 
laclrte nccum~latlon. A previously reported computer pra- 
gram (10.11) was used to estimate the oxygen consumption 
when the blood lactate exceeded 1.3 m&f. This value was 
chosen because it was I SD above the normal lactate value 
at rest in our laboratory. The reproducibility of measure- 
ments and correlation with dir& measmement in cardiac 
patients have been reported (IO.1 I). The program utilizes 30 
s mes~urements of oxygen consumption and minute ventila- 
tion made during the exercise test. These data were entered 
on a floppy disk for subsequent estimation of the oxygen 
cottsumplion when blood lactate exceeded 1.3 mh’. 
End&tceexcrclx test(conslanl work load). On the basis 
of tix oxygen consumption data from the first two maximal 
exercise tests, a level of exercise that correrponded to 70% 
of peak oxygen consumption was chosen. Anestimate of the 
treadmill settings to elicit this level of oxygen consumption 
was made. This work load was used for each of the three 
endurance tests irrespective ofany possible changes in peak 
oxygen consumption during subsequent tests. Before the 
endurance test, patients were instructed lo continue exercis- 
ing until exhausted. During the test the ECG, heart rate and 
bloJd pressure were recorded every 3 min. Expired gas was 
collected 2nd oxygen consumption was measured every 30 s. 
The total duration of exercise was noted. The heart rate, 
blood pressure and oxygen consumption during the final 3 
mitt of exercise were recorded. Endurance capacity was 
delined as the length of time that individuals performed at 
the constant work load. 
Statistical an&is. Values are presented as mean values 
? SEM. Analysis of variance was used to test if there was a 
difference with treatment p&xl (weeks 2, 6, and 1 I) and 
also with treatment (single blind placebo, double blind 
placebo, amlodipine). A paired Student’s t test was used to 
test the significance of differences between amlodipine and 
placebo therapy. 
ReSUlts 
F’atienk characleri~tics (Table 1). The mean exercise time 
during the screening symptom-limited exercise test was 499 
+ 39 s and the peak oxygen consumption was 16.9 f 1.4 ml/ 
kg per min. The patients exercise tolerance was moderately 
impaired. the exercise capacity representing 58 * 4% of the 
age- and gender-adjust:d normal value (12). Of 13 patients 
who ttndetwent cardiac catheterization within 2 years of this 
study. 6 (46%) had three vessel coronary artery disease, 4 
(31%) had two vessel disease and 3 (23%) had single vessel 
disease. Themeanleft ventricullrejectionfra~tionat rest for 
this group was 0.58 * 0.04. 
Symptomatic reqwse (Fig. 1). Angina Frequency was 
decreased significantly and to a similar degree during both 
double blind~placebo~and amlodipini periods. Analysts of 
variance indicated that this was a P&ad effect rather than a 
treatment &et. Nitroglycerin consumption was reduced 
signilicardly only during amlcdipine therapy. Three patients 
could not maintain a diary satisfactorily and were not 
included in this aspect of da*3 analysis. 
Maximal twrcise test @ii. 2). Peak oxygen consumprwn 
was similar during the single blind placebo period (IS.7 t I. I 
ml/kg per min) and the double blind placebo period (18.2 ? 
1.8 mlikg per min) (p = NS). Treatment with amlcdipine 
significanrly increased peak oxygen consumption to 20.4 t 
I .6 mlikg per min when compared with double blind placebo 
treatment (p < 0.05). The oxypn consumption at the lactate 
threshold during amladipine treatment (14.1 ? I.0 ml/kg per 
mini tended to be higher than during the single blind placebo 
period (13.6 C 0.8 ml&g per min. p = NS) and the double 
blind placebo period (12.9 + I.1 svkg per min. p = NSI. 
There were no significant changes during maximal exercise 
testing beween the amlcdipine period and the double blind 
placebo period in total exercise ;ime, time to I mm ST 
segment depression and time to anpina pectoris (Table 2). 
Fiyre 2. Yalue5 ,mean * SEM, for peak oxygen consumption 
(VO,) for the three lreahnent periods in 14 patients. Abbreviations 
ai in Figure I, 
Mnrbnol ST depression was significanlly reduced during 
double blind placebo (I.1 * 0.1 mm. p -C O.tMSl and 
amlcdipine trealmenl 10.9 ? 0.1 mm, p < O.M)I) when 
compared with single blind placebo 11.6 ? I.1 mml. The 
product of heart rate and systolic blood pressure (rate- 
pressure pmducrl WBP examined at rest. durina a common 
submaximal work load and at peak exercise anb no signiti- 
cant differences were observed (Table 21. 
Endurance exercise test (Fig. 3). Endurance time at 70% 
peak oxygen consumption with the use of the constant work 
load protocol was similar during the single blind placebo 
period (IS.2 ? 1.5 min) and the double blind placebo period 
(IS.8 1 2.1 min) (p = NS). Treatment with amlodipine 
significantly prolonged endurance time to 20.2 r 2.5 min 
(smgle blind placebo, p c 0.0s; double blind placebo, p < 
0.W). Amlodipine did not alter heart rate !I24 * 14 versus 
I23 + 19 beatsimin. p = NS) or rate-pressure pwduct (I93 + 
45 X IO-‘versus 207 + 51 x 10-2. p = NS) during constant 
level endurance testing compared with double blind placebo. 
Figure 3. “aluestmean? SEM,f.rendurancetime (min,durin,,an 
exercise lest performed at 707~ of peak exercise capacity in I6 
patients. Abbreviations as in Figure I. 
Oxygen consumption during the constant work load was not 
altered by amlcdipine therapy (14.1 + I.2 ml/kg per min) 
compared with placebo periods (double blind placebo 13. I k 
1.2; single blind placebo 13.8 * 1.2 ml/kg per min, p = NS). 
The respiratory exchange ratio was similar for the three 
periods (single blind placebo. 0.92 t 0.04; double blind 
placebo, 0.93 f 0.03 and amlodipine, 0.93 * 0.03). 
The oxygen consumption and respiratory exchange val- 
ues indicate that patients exercised at the same level of 
intensity during each test and that the improvement in 
exercise duration was not due to altered effort or decreased 
oxygen consumption. During the endurance test, several 
patients experienced angina, but in none af the tests was this 
a limiting symptom All patiems stopped exercising because 
of fatigue. 
Corrrlnlion belwren endurance performancr and peak 
exercise performance. The improvement in wbmaxmxl eo- 
durance capacity produced hy treatment wi!h amlodlpme did 
not correlate with rhe change I” peak oxygen consumptmn 
(r = 0.19. Bccausc lhcre was no ~gmticant change ,n 
oxygen consumption at the blood lactate threrhold. an 
attempt to correlate this varrable and endnrance cnpac,,y 
was not made. 
Side effe& patients tolerated amlodipme and placebo 
therapy without side effects. Biochemical and hemarologic 
profiles were not altered by amlodipine. 
Discussion 
Evaluation of effectiveness of iheracy. Treatment with 
amlodipine. Ill &day, resulted in a modest increase in peak 
oxygen consumption and a 30% increase in endurance time. 
Unlike many studies with other calcium slow channel block- 
ing drugs, &r investigation did not show an improvement m 
exercise duration and time to angina during a progrcnivc 
incresse in load to a maximal level. Our results suggest that 
if a progressive work load test is used. peak oxygen con- 
sumption may be a more reliable measurement than exercise 
time because it is not influenced by patient efforton. 
Although the improvement seen in peak oxygen con- 
sumption was m&est (10%). the improvemem in endurance 
capacity was much grearer (30%). Subma:;imal exercne 
test& offers several potential advantages in evaluating drug 
therapy in patients with coronaty zxtely disease. The dora- 
tion of exercise performed at the submaximal levels may 
have more relevance to the performance and tolerance of 
daily activity than does maxiinal exercise capacity Submax- 
imal exercise does not require the same degree of musculos- 
keletal strain seen with maximal effort and thus may enhance 
the comfon of the procedure. pmtirutarly for elderly pa- 
tients. 
Meeha&ns of iiprovenwnt in endonmee capacity. The 
d.?erminants of submaximal exercis: pe-fommce ,n pa- 
tients with coronary artery disease a~: not as clearly delin- 
eated as those for maximal exercise performance. The limits 
to submaximal exercise are thought to involve peripheral 
mechanisms as welt as rardiac~pzkmnance. ia rkmd 
subjects and, in particuiar. athletes, the blood lactate thresh- 
old correlates with endurance performance (4-7), bb a 
similar relation does not exist for patients with coronary 
artery disease. Our results suggest that the lactate threshold 
is not the major determinant of endurance capaoty. There 
was a trend fo! the lactate threshold to increaSe with 
amlodipine and the noninvasive determinatmn of the lactate 
threshold may not b-e sensitive enough to detect small 
changes. In normal subjects. physical training causes reduc- 
tions in t;ood lactate levels at a given work load (13). 
although it is being debated whether incicased cleamnce or 
reduced production is the mech;mi.m (141. Sulbvan et al. 
(19 icputwJ improved exercise performance m patients 
wth cornnary anery dware a~ a rewlt of physical trxning. 
although 3 ilgnilicant change in venrilatcrg thrcsho!d was 
not ohrerved. They conc!oded. as we have for amlodipine, 
that m pi!fientC with coronary artery disesie factors other 
than the venulatory threshold were respanrible for the 
incrcxc in treedmill wualkmg time. Another posrlblc fwmr 
that may contribute to endurance performance is tempera- 
ture regulation. If amlodipitie caused arterialar dilation of 
the skin blood vcsscls. heat loss during exercw may have 
heen promoted and endurance capacity improved. Further 
wdics need 10 be performed to address this iscue. 
Yeehonism of improvement in peak performa~e. Other 
studs, demons,fi,!ing improved cxcreisc capaciry airh ccl- 
cium FIOW channel blocking dmps hwe chow a reduction in 
rate-prewure pmduct as the major mechanism ior m~proved 
psrformance in patients with coronary artery disease. Cal- 
cium antagomsts primarily cause a reduction in myacardial 
oxygen dcmrnd (lb). although ahanced coronary blood 
Row car. OCCI,F (17,. In the precent Wdy there was a ,reF.d 
toward a lower rate-pressure product with amlodipme mat- 
mcnt. but this failed to reach statistical cigmticance. The 
improvement in endurance capacity and peak oxygen con- 
sumptmn mtght have been greater if a higher dose of 
amlodipine had been used. Presumably this would cause a 
greater reduction in rate-pressure product. Suboptimal dos- 
age may also account for the lack of effect on time to angina 
and Ihe mild mcrease xen in time to I mm ST segment 
depression. 
Compartsan with other antiangjiml.thrrapy. Studic,s with 
a variety of beta-receptor blocking drugs. nitrates and cal- 
cium slow channel bkxking drugs have shown improvement 
in total duration of exerctse and time to onset of angina and 
ST depression, hut in the majority of slodies endurance 
performance was not evaluated. Comparisons be!ween am- 
lodipine and other forms of therapy are needed to fully 
evaluate the role of this agent in treating patients with 
angina. 
Clinical imptlltiorrs. Submaximal exercise performance 
and peak oxygen consumption were improved by amlodi- 
pine. 10 m&lay, in patients with angina. The ircrease in 
endurance capacity did not correlate with changes in peak 
oxygen consumption, suggesting that they provide indepm- 
dent measures of abtianginal eBicacy. Diary records of 
angina frequency and nitroglycerin consumption were less 
reliable and are less helpful for documenting the efficacy of- 
drug. The usefulness of endurance exercise testing for es- 
kesring therapy should be evaluated further. Our results with 
this technique are encouraging and it may he more applicable 
than maximal exercise testing for assessing the effect of 
interventions on daily activities. 
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